Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Rakesh Jain
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
XTuit Pharmaceticals
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Jain is a co-founder and Board Member of XTuit Pharmaceuticals, a company developing novel microenvironment-activated therapeutics. In addition, Dr. Jain is an inventor of technology licensed to the company through the hospital. The goal of this research project is to provide novel mechanistic insights into reprogramming the immunosuppressive tumor microenvironment of PDAC into an immunostimulatory one. The results of the research may be of interest to XTuit. The institution determined that, given the magnitude of the financial interest in addition to the close connection between the aims of the company’s interests and the aims of the research, Dr. Jain’s financial interest could directly and significantly affect the design, conduct, or reporting of the research.
Reprogramming PDAC tumor microenvironment to improve immunotherapy
Narrative The goal of this U01 and the future collaborations with the PDAC Consortium is to provide novel mechanistic insights into reprogramming the immunosuppressive tumor microenvironment of PDAC into an immunostimulatory one. Our approach to achieve this will be to use widely prescribed and inexpensive inhibitors of the angiotensin II signaling. Our preliminary data show that angiotensin II signaling mediates not only the desmoplastic reaction characteristic of PDACs, but also immunosuppression via effects on innate and adaptive immunity. The resulting data will directly inform the design of a clinical trial to test the efficacy of combining losartan?an angiotensin II signaling inhibitor?and cytotoxic agents with immune checkpoint blockers in a multi-institutional trial led by our clinical collaborators at the MGH Cancer Center. By altering the tumor microenvironment in this manner, we aim to overcome resistance to standard and emerging systemic therapies for this intractable disease.
Filed on October 02, 2017.
Tell us what you know about Rakesh Jain's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Rakesh Jain filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Rakesh Jain | Massachusetts General Hospital | Conflict of Interest | XTuit Pharmaceticals | $20,000 - $39,999 |
| Rakesh Jain | Massachusetts General Hospital | Conflict of Interest | XTuit Pharmaceticals | $20,000 - $39,999 |
| Rakesh Jain | Massachusetts General Hospital | Conflict of Interest | Xtuit Pharmaceuticals, Inc. | $5,000 - $9,999 |
| Rakesh Jain | Massachusetts General Hospital | Conflict of Interest | XTuit Pharmaceticals | Value cannot be readily determined |
| Rakesh Jain | Massachusetts General Hospital | Conflict of Interest | Xtuit Pharmaceuticals, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.